Oxonol vs MIT vs 7-OH: Product Identity Guide

Oxonol, MGM-15, 7-OH, and MIT can appear in the same retail conversation, but they do not identify the same thing. Start with the product’s ingredient line, then connect that identity to a dated regulatory source.

How their expected human effects differ

MIT, 7-OH, and MGM-15 are psychoactive and opioid-receptor active, but the names are not interchangeable. Receptor activity, metabolism, commercial concentration, and the quality of human evidence differ among them.

Laboratory research finds that 7-OH activates human mu-opioid receptors more potently than mitragynine. A 2025 analysis of MGM-15 tablets and receptor binding found MGM-15 had still greater binding affinity than 7-OH at human mu- and delta-opioid receptors, although MGM-15 has not been studied in controlled human administration. MIT is therefore the more established and plant-connected alkaloid lane, not an effect-equivalent substitute. Nausea, constipation, drowsiness, tolerance, dependence, and withdrawal remain relevant across opioid-receptor-active products.

The most important difference: brand name versus substance name

Oxonol is the manufacturer's brand name for a product it describes as containing MGM-15 and mitragynine. MGM-15 is one of the substances placed in Schedule I by DEA's August 26, 2026 temporary order. A retail name does not remove a named ingredient from the scope of an order that addresses that ingredient.

Oxonol vs 7-OH

Oxonol is not simply another spelling of 7-OH. Its manufacturer describes MGM-15 as part of the formula, while DEA identifies MGM-15 as dihydro-7-hydroxymitragynine, a derivative of 7-hydroxymitragynine. DEA's August 26 order scheduled MGM-15, MGM-16, and mitragynine pseudoindoxyl. The proposed threshold for 7-OH remains a separate federal process, and the two records must be read on their own terms.

The FDA also distinguishes naturally occurring trace 7-OH in botanical material from unlawful products sold with high concentrations of 7-OH. Its consumer update states that there are no FDA-approved products containing 7-OH. That is not a statement that every product using a different brand name is approved or unaffected.

Oxonol vs MIT

MIT means mitragynine, a naturally occurring kratom alkaloid that is chemically distinct from MGM-15. Concentrated MIT tablets and powders should identify the mitragynine amount or percentage, package count or net weight, and the scope of any supporting laboratory document. Those fields let a buyer compare an identified kratom alkaloid product without confusing it with an MGM-series formulation.

Kratom Paradise’s MIT catalog does not present its products as Oxonol, MGM-15, 7-OH, a therapeutic substitute, or an equivalent experience. For shoppers prioritizing a distinct ingredient identity, familiar tablet or powder formats, and qualified source-material documentation, the MIT catalog is the more straightforward comparison path.

Form factor does not establish chemical identity

Oxonol products and MIT products may both appear as chewable tablets. A gummy, shot, tablet, capsule, or powder describes physical form; it does not tell you which alkaloid is present. Two chewable tablets can have entirely different named ingredients and regulatory questions. Compare the ingredient line before comparing flavor, count, or convenience.

What to compare before choosing a product lane

• Identity: Is the label MIT, MGM-15, 7-OH, pseudoindoxyl, a blend, or only a branded phrase?
• Disclosure: Are the active ingredients and their basis stated plainly?
• Documents: Does a report cover source material or the finished product, and does the sample match?
• Status: Is the legal statement tied to the current federal, state, and local record?
• Format: Does the package provide a tablet count, net weight, and consistent selector fields?

The federal distinction on August 26, 2026

DEA's temporary order placed MGM-15, MGM-16, and mitragynine pseudoindoxyl in Schedule I. Because the manufacturer description cited here identifies MGM-15 in Oxonol, the order is directly relevant to that formula. Mitragynine remains a separate named alkaloid, and the order did not place mitragynine itself in Schedule I. The proposed threshold for 7-OH, state and local rules, and the actual product record still require separate checks. Use the federal status tracker for the controlling documents.

Continue with the Oxonol and MGM-15 guide, 7-OH vs kratom vs MIT comparison, or MIT chewable tablet collection.

This comparison is educational product and regulatory information, not medical or legal advice.